{"protocolSection":{"identificationModule":{"nctId":"NCT05657470","orgStudyIdInfo":{"id":"Y (2022) 187"},"organization":{"fullName":"General Hospital of Shenyang Military Region","class":"OTHER"},"briefTitle":"Rescue Thrombolysis for Medium Vessel Occlusion (RESCUE-TNK)","officialTitle":"Rescue Thrombolysis for Medium Vessel Occlusion (RESCUE-TNK): a Prospective, Randomized, Open-label, Blinded End Point, and Multicenter Trial"},"statusModule":{"statusVerifiedDate":"2023-03","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2023-03-21","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-03-15","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-03-15","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-12-02","studyFirstSubmitQcDate":"2022-12-10","studyFirstPostDateStruct":{"date":"2022-12-20","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-03-21","lastUpdatePostDateStruct":{"date":"2023-03-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"PRINCIPAL_INVESTIGATOR","investigatorFullName":"Hui-Sheng Chen","investigatorTitle":"Head of Neurology","investigatorAffiliation":"General Hospital of Shenyang Military Region"},"leadSponsor":{"name":"General Hospital of Shenyang Military Region","class":"OTHER"},"collaborators":[{"name":"Cerebrovascular Disease Collaboration & Innovation Alliance of Liaoning","class":"UNKNOWN"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The best reperfusion strategy for medium-sized vessel occlusion (MeVO) is not well established. Given the proven treatment effect of intra-arterial thrombolysis in patients with large vessel occlusion (LVO), the investigators hypothesized that intra-arterial tenecteplase (TNK) could increase the recanalization rate of MeVO and thus improve clinical outcome. The current study aimed to explore the safety and efficacy of intra-arterial TNK in patients with MeVO."},"conditionsModule":{"conditions":["Stroke, Ischemic"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2","PHASE3"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"SINGLE","whoMasked":["OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":80,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"TNK group","type":"EXPERIMENTAL","interventionNames":["Drug: Tenecteplase"]},{"label":"control group","type":"NO_INTERVENTION"}],"interventions":[{"type":"DRUG","name":"Tenecteplase","description":"intra-arterial tenecteplase","armGroupLabels":["TNK group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"proportion of patients with successful Medium vessel occlusion (MeVO) recanalization","description":"successful MeVO recanalization is defined as the expanded treatment in cerebral ischemia (eTICI) score 2b67-3 in the territory of the target occluded MeVO artery","timeFrame":"immediately after finishing intra-arterial tenecteplase"}],"secondaryOutcomes":[{"measure":"proportion of modified Rankin Scale (mRS) 0-1","description":"mRS scores range from 0 to 6, with higher scores indicating worse outcome","timeFrame":"Day 90"},{"measure":"proportion of modified Rankin Scale (mRS) 0-2","description":"mRS scores range from 0 to 6, with higher scores indicating worse outcome","timeFrame":"Day 90"},{"measure":"distribution of modified Rankin Scale (mRS)","description":"mRS scores range from 0 to 6, with higher scores indicating worse outcome","timeFrame":"Day 90"},{"measure":"incidence of early neurological improvement","description":"early neurological improvement is defined as a decrease of more than 4 points or reaching 0 points in NIHSS score, compared with baseline","timeFrame":"24 (-6/+24) hours"},{"measure":"Changes in National Institute of Health stroke scale (NIHSS)","description":"NIHSS scores range 0-42, with higher scores indicating greater stroke severity","timeFrame":"24 (-6/+24) hours"},{"measure":"rate of visual recovery in patients with posterior cerebral artery occlusion","timeFrame":"7 days or at hospital discharge"},{"measure":"proportion of symptomatic intracranial hemorrhage","description":"symptomatic intracranial hemorrhage is defined as an increase in the NIHSS score of ≥4 points as a result of the intracranial hemorrhage","timeFrame":"24 (-6/+24) hours"},{"measure":"proportion of parenchymal hematoma type 1 and 2","timeFrame":"24 (-6/+24) hours"},{"measure":"all serious adverse events","timeFrame":"24 (-6/+24) hours"},{"measure":"all-cause death","timeFrame":"7 days"},{"measure":"recurrent stroke, cardiovascular events, other vascular events and death","timeFrame":"90 days"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Medium vessel occlusion (MeVO), referring to M2-3 of MCA; A1-3 of ACA; P1-3 of PCA; PICA, AICA or SCA (including primary, distal embolism in the same region after thrombectomy or concurrent embolism in other regions).\n\n   * Primary MeVO as detected by the first DSA examination or secondary MeVO after mechanical thrombectomy for large vessel occlusion;\n   * MeVO causes neurological deficits in motor strength, language, vision etc;\n   * Endovascular mechanical thrombectomy cannot be performed as assessed by the investigator;\n   * Absence of parenchymal hematoma on CT images performed in the angio suite.\n3. Within 24 hours from symptom onset;\n4. Signed informed consent by patient or patient's legally authorized representative.\n\nExclusion Criteria:\n\n1. Patients with completed infarction in the territory of the MeVO on non-contrast CT;\n2. Patients with intracranial hemorrhage;\n3. Coagulation disorders, tendency for systemic hemorrhagic, thrombocytopenia (\\<100,000/mm3);\n4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n5. After mechanical thrombectomy, severe and sustained (\\> 5 minutes) uncontrolled hypertension (systolic blood pressure over 180mmHg or diastolic blood pressure over 105 mmHg);\n6. Patients with contraindication or allergy to any ingredient of study medication;\n7. Pregnancy, plan to get pregnant or active lactation;\n8. The estimated life expectancy is less than 6 months due to other serious diseases;\n9. Other conditions unsuitable for this clinical study as assessed by researcher.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"locations":[{"facility":"General Hospital of Northern Theater Command","status":"RECRUITING","city":"ShenYang","zip":"110840","country":"China","contacts":[{"name":"Zi-Ai Zhao","role":"CONTACT","phone":"+862428897491","email":"zhaoziai@hotmail.com"}],"geoPoint":{"lat":41.79222,"lon":123.43278}}]},"ipdSharingStatementModule":{"ipdSharing":"UNDECIDED"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Stroke, Ischemic","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000077785","term":"Tenecteplase"}],"ancestors":[{"id":"D000005343","term":"Fibrinolytic Agents"},{"id":"D000050299","term":"Fibrin Modulating Agents"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"}],"browseLeaves":[{"id":"M1911","name":"Tenecteplase","asFound":"Early Intervention","relevance":"HIGH"},{"id":"M8163","name":"Fibrinolytic Agents","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}